This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Cytek Biosciences, Inc.
11/4/2026
Hello and thank you for standing by. My name is Lacey and I will be your conference operator today. At this time, I would like to welcome everyone to the SciTech Biosciences third quarter 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the call over to Mark Meehan, Head of Investor Relations. Please go ahead.
Thank you, Operator. Joining me today from Scitech are Wenbin Jiang, CEO, and Bill McCombe, CFO. Earlier today, Scitech Biosciences released financial results for the third quarter ended September 30, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investors at scitechbio.com. A copy of the news release is also available on the investor relations section of Scitech's website at investors.scitechbio.com. Please note that we will be referencing a slide presentation during the call today that has been posted to the investor section of our corporate website. As a reminder, on slide two, We will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding CITAC's business plans, strategies, opportunities, and financial projections. These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated in these statements. Additional information regarding these risks and uncertainties appears in our slide presentation in the section entitled Forward-Looking Statements in the press release CITEC issued today and in CITEC's filings with the SEC. This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Additional information regarding our use of non-GAAP financial measures, including reconciliations to the most directly comparable GAAP financial measures, may be found in our slide presentation and in today's press release. While the company believes these non-GAAP financial measures provide useful information for investors, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. This call will also provide a brief update about our active patent litigation. For more complete information about this case, as well as counter suits that we have instituted, Please refer to our previous press release as well as our SEC filings, including our Form 10Q to be filed today. Except as required by law, Scitech disclaims any duty to update forward-looking statements, whether because of new information, future events, or changes in its expectations. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 4, 2026. With that, I will turn the call over to Wenbin.
Thanks, Mark. Welcome, everyone, and thank you for your interest in SciTech. On today's call, I will start with a discussion on our performance in the third quarter and review some business highlights before turning the call over to Bill for a detailed look at our financial results and our full-year outlook. Turning to slides three and four. We delivered another solid result in the third quarter with revenue of $53.2 million, an increase of 2% year-over-year. Our third quarter was highlighted by growth in the U.S., driven by continued strong demand for our high-end full-spectrum profiling instruments led by Aurora Evo, the double-digit growth in our service business. and by our robust growth margin performance. Growth in the third quarter was led by the U.S., where revenue grew 12% year-over-year to $30.4 million, continued strong momentum from the first half driven by instrument sales to academic and government customers, and continued service growth. In a year, Third quarter revenue was $12.5 million, up 1% year over year, a positive sign after a challenging first half that reflected improving instrument sales to academic and government customers. Total APEC revenue, including China, was $8.3 million, up 5% sequentially, versus Q2, while being down 25% compared to a strong Q3 last year. Turning to slide five, the third quarter was highlighted by success at the high end where our technology leadership continues to shine. Customers are choosing Aurora Evo as it lets them run large panels and get consistent reproducible data at higher throughput. The automation configuration we introduced last quarter further increased the value to customers with the API for automated place handling system fitting well into the high volume workflows of biopharma and CRO customers. Combined, Aurora and Aurora EVO placements grew 23% year over year, with EVO placements nearly doubling year over year, reflecting robust demand for our next generation platform. As a result of strong placements, High-end full spectrum profiling instrument revenue grew 11%. Across the broader business, we added a total of 140 instruments in the quarter, bringing our total installed base to 4,073 units. Borealis, our newest platform, which we introduced last quarter, is receiving strong interest from customers in both the academic and biopharma markets. And we doubled the size of our early access program during Q3. As a reminder, Borealis is a seven laser full special profiling cytometer with 60 color performance already demonstrated and a clear path to go higher as new dyes and panels are developed. It will also include integrated imaging capabilities when we get to full commercial launch. Paired with our new proprietary C-flow reagents, Borealis enables 60 color panels in a single tube while also supporting nanoparticle analysis and higher sampling rates. Early access program customers are excited about how these capabilities can enhance insights and Accelerate Discovery in their labs. We will continue to expand the early access program in the fourth quarter with a broader commercial launch planned for fiscal year 2027. Turning to slide six, during the third quarter, we launched a new site cloud analysis tool, the industry's first end-to-end platform that integrates The entire flow cytometry workflow from panel design to data analysis into one system. This will allow researchers to have a seamless experience from experiment planning through data analysis, reducing the need to move between systems or recreate workflows. Cloud analysis is available in the U.S. through CYCET Cloud Premium. a new subscription tier that adds cloud-based data analysis and online data storage. The launch is an important milestone towards our vision of SiteCloud as a comprehensive digital ecosystem that supports pro-psychometry workflows from beginning to end. As of the end of the third quarter, the total SiteCloud user base is approaching 30,000, up more than 20% since the start of the year. Our recurring revenue base continued to grow in the third quarter. Combined service and reagent revenue was $19.1 million in June 3, 2026 and represented 36% of CITES' last 12-month revenue, up from 33% for the 12 months ended September 30, 2025. We expect recurring revenue to represent an increasing percentage of total revenue over time. During the quarter, we also had important developments in our patent litigation case. As we announced on August 21st, a jury in the U.S. District Court for the District of Delaware found in our favor on three of the four assertive claims. are in both known infringement and invalidity for each of those three claims. On the fourth claim, the jury found no legal infringement, but did find infringement under the doctrine of equivalence. We do not believe that the applicable legal criteria for infringement under the doctrine of equivalence have been met. We filed post-trial to our motions asking the court to overturn the verdict on this and other grounds. And we intend to pursue all available legal remedies. The jury's verdict does not require any change to our product offering or operations, and our ability to sell and ship products is not affected. Notably, the patent at issue is a U.S. patent and only applies to sales of instruments made in or imported into the United States. Finally, I wanted to share an update on the new business unit structure we introduced earlier this year. After careful review, we have decided to postpone the implementation of these business units until the start of 2027. We judged the near-term risk of moving to our new organization structure Thank you very much. We were pleased with the overall performance of our business. The third quarter was highlighted by continued success of our high-end Aurora Evo and Borealis analyzers by the double-digit growth in our service business, and as Bill will detail shortly, the strong execution from our operations team, which resulted in our best third quarter growth margin since 2020. with top-line performance in line with our proud expectations. We are reiterating the midpoint of our full-year 2026 W guidance. And with that, I will now turn the call over to Bill for additional details on our Q3 financials and our full-year outlook.
You're reading a preview of the CTKB Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing